ReviewAnti-cancer agents in medicinal chemistry2026
Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer.
Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing interest in glycoconjugates as potential chemotherapeutic agents against cancer stems from their ability to selectively target biological processes associated with tumor growth and metastasis. Glycoconjugates- compounds in which carbohydrates are covalently linked to proteins, lipids, or other bioactive molecules-have shown considerable promise in enhancing both the efficacy and selectivity of cancer therapies. This review highlights recent advancements in the development of glycoconjugates, focusing on their roles in modulating tumor-associated glycan interactions, improving drug delivery, and overcoming resistance mechanisms. Key breakthroughs include the synthesis of novel glycoconjugate compounds that exhibit enhanced cytotoxicity toward cancer cells while minimizing effects on normal tissues. Additionally, innovative strategies utilizing glycoconjugates as drug carriers or in combination therapies have demonstrated potential in preclinical and clinical studies. These developments suggest that glycoconjugates could play a pivotal role in the future of cancer treatment, offering new avenues for targeted and personalized therapeutic approaches.
Indexed as
Identifiers
42897893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.